FDA requests additional development activities to support approval of Adventrx's ANX-514 Feb. 16, 2011
Yale University scientists synthesize the aglycon of lomaiviticin A, a promising anticancer agent Feb. 16, 2011
Endpoint met in first part of phase II trial of Reolysin and gemcitabine in pancreatic cancer Feb. 15, 2011
RSS